Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LAP3 | P28838 | 4/20 | 0.50 |
| ▸ | ANPEP | P15144 | 2/20 | 0.50 |
| ▸ | RNPEP | Q9H4A4 | 2/20 | 0.50 |
| ▸ | DNPEP | Q9ULA0 | 2/20 | 0.50 |
| ▸ | CSNK1E | P49674 | 1/20 | 0.49 |
| ▸ | CTSD | P07339 | 5/20 | 0.43 |
| ▸ | BACE1 | P56817 | 5/20 | 0.43 |
| ▸ | BACE2 | Q9Y5Z0 | 5/20 | 0.43 |
| ▸ | F2 | P00734 | 2/20 | 0.40 |
| ▸ | CASR | P41180 | 1/20 | 0.40 |
| ▸ | SPPL2A | Q8TCT8 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Hydrochloric Acid SCHEMBL5222718 | 0.99 | LAP3 (0.49) | LAP3ANPEPRNPEPDNPEPCSNK1E | |
| SCHEMBL5219469 | 0.87 | CSNK1E (0.59) | LAP3ANPEPRNPEPDNPEPCSNK1E | |
| SCHEMBL5217674 | 0.84 | CSNK1E (0.49) | LAP3ANPEPRNPEPDNPEPCSNK1E | |
| SCHEMBL5220403 | 0.83 | LAP3 (0.53) | LAP3ANPEPRNPEPDNPEPCSNK1E | |
| SCHEMBL5396321 | 0.82 | CSNK1E (0.51) | LAP3ANPEPRNPEPDNPEPCSNK1E | |
| SCHEMBL5224141 | 0.82 | CSNK1E (0.55) | LAP3ANPEPRNPEPDNPEPCSNK1E | |
| Hydrochloric Acid SCHEMBL5217902 | 0.81 | ADRB1 (0.41) | LAP3ANPEPRNPEPDNPEPCSNK1E | |
| Hydrochloric Acid SCHEMBL5217528 | 0.81 | CSNK1E (0.50) | LAP3ANPEPRNPEPDNPEPCSNK1E | |
| SCHEMBL5218444 | 0.81 | CSNK1E (0.47) | LAP3ANPEPRNPEPDNPEPCSNK1E | |
| Hydrochloric Acid SCHEMBL5226706 | 0.81 | DPP4 (0.35) | LAP3ANPEPRNPEPDNPEPCSNK1E |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1692143-B1 | TRICYCLIC INDOLE HYDROXYETHYLAMINE DERIVATIVES AND THEIR USE IN THE TREATMENT OF ALZHEIMER'S DISEASE | GLAXO GROUP LTD (GB) | 2008-11-12 | — | — | EP | disclosed |
| US-7253198-B2 | Hydroxyethylamine derivatives for the treatment of Alzheimer's disease | GLAXO GROUP LIMITED (GB) | 2007-08-07 | — | — | US | disclosed |
| US-20060229302-A1 | Tricyclic indole derivatives and their use in the treatment of alzheimer's disease | GLAXO GROUP LIMITED (GB) | 2006-10-12 | — | — | US | disclosed |
| US-20060025459-A1 | Hydroxyethylamine derivatives for the treatment of alzheimer's disease | GLAXO GROUP LIMITED (GB) | 2006-02-02 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060229302-A1 | Tricyclic indole derivatives and their use in the treatment of alzheimer's disease | BACE2, BACE1, PSEN2 | LAP3 399/4885ANPEP 85/4885RNPEP 235/4885 |
| US-20060025459-A1 | Hydroxyethylamine derivatives for the treatment of alzheimer's disease | BACE2, PSEN2, BACE1 | LAP3 259/4885ANPEP 47/4885RNPEP 239/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.